araag2/HINT huggingface dataset:
Clinical trial NCT01221870 (phase 2, status: unknown status)
Conditions: breast neoplasm
ICD codes: C79.81, D24.1, D24.2, D24.9, D49.3, C44.501, D48.60
Drugs: tesetaxel once every 3 weeks, tesetaxel once weekly
SMILES: CN(C)C[C@@H]1O[C@H]2[C@@H](O1)[C@]1(C)CC[C@H]3OC[C@@]3(OC(C)=O)[C@H]1[C@H](OC(=O)C1=CC=CC=C1)[C@]1(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C3=C(F)C=CC=N3)C(C)=C2C1(C)C, CN(C)C[C@@H]1O[C@H]2[C@@H](O1)[C@]1(C)CC[C@H]3OC[C@@]3(OC(C)=O)[C@H]1[C@H](OC(=O)C1=CC=CC=C1)[C@]1(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C3=C(F)C=CC=N3)C(C)=C2C1(C)C
Eligibility criteria:

        Primary Inclusion Criteria:

          -  Female

          -  At least 18 years of age

          -  Histologically or cytologically confirmed adenocarcinoma of the breast

          -  Stage IV disease

          -  HER2 status negative

          -  Measurable disease (revised RECIST; Version 1.1)

          -  Eastern Cooperative Oncology Group performance status 0 or 1

          -  Life expectancy of at least 3 months

          -  Chemotherapy naïve or 1 prior chemotherapy regimen in the adjuvant setting (Prior
             taxane-based adjuvant therapy allowed provided patient had a disease-free interval of
             at least 12 months after completing this adjuvant therapy)

          -  Prior hormonal therapy, aromatase inhibitor therapy, and immunotherapy allowed

          -  Prior radiotherapy in the adjuvant setting allowed provided that less than 25% of the
             bone marrow had been irradiated

          -  Adequate bone marrow, hepatic, and renal function, as specified in the protocol

          -  At least 4 weeks and recovery from effects of prior surgery, hormonal therapy,
             aromatase inhibitor therapy, immunotherapy, radiotherapy, or other therapy with an
             approved or investigational agent

          -  Ability to swallow an oral solid-dosage form of medication

        Primary Exclusion Criteria:

          -  Known metastasis to the central nervous system

          -  History of other malignancy within the last 5 years other than curatively treated
             basal and squamous cell carcinoma of the skin or carcinoma of the cervix in situ

          -  Significant medical disease other than Stage IV breast cancer

          -  Presence of neuropathy > Grade 1 (NCI CTC, Version 4.0)

          -  History of hypersensitivity to a taxane

          -  Need to continue any regularly-taken medication that is a potent inhibitor or inducer
             of the CYP3A pathway or P-glycoprotein activity
Clinical trial NCT01226797 (phase 2, status: terminated)
Conditions: hepatitis c, chronic
ICD codes: B18.2, B18.0, B18.1, B18.8, B18.9, K71.3, K71.4
Drugs: placebo, pf-04136309
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Reason stopped: 
    see termination reason in detailed description.
  
Eligibility criteria:

        Inclusion Criteria:

          -  Chronic HCV infection

          -  ALT >1.5 but <10 times upper limit of normal

        Exclusion Criteria:

          -  Decompensated or severe liver disease defined by one or more of the following
             criteria:

        Prior liver biopsy showing cirrhosis.

          -  International Normalized Ratio (INR) greater than or equal to 1.5.

          -  Total bilirubin greater than or equal to 1.5X ULN, or >2X ULN for unconjugated
             bilirubin.

          -  Serum albumin below normal.

          -  ALT or aspartate aminotransferase (AST) >10 x ULN.

          -  Evidence of portal hypertension including splenomegaly, ascites, encephalopathy,
             and/or esophageal varices.

          -  Presence of human immunodeficiency virus (HIV).

          -  Co-infection with hepatitis B virus (HBV).

          -  Co-infection with Epstein Barr Virus (EBV) and/or Cytomegalovirus (CMV).
Clinical trial NCT00260065 (phase 2, status: completed)
Conditions: myelodysplastic syndrome
ICD codes: D46.9, D46.C, D46.Z
Drugs: decitabine
SMILES: CN(C)\N=N\C1=C(N=CN1)C(N)=O
Eligibility criteria:

        Inclusion Criteria:

          1. Must sign an Institutional Review Board (IRB) -approved informed consent form.

          2. Must be 18 years of age or older.

          3. Must have a diagnosis for MDS fitting any of the recognized French-American-British
             (FAB) classifications and International Prognostic Scoring System (IPSS) greater than
             or equal to 0.5 as determined by Complete Blood Count (CBC), bone marrow assessment,
             and cytogenetics within 28 days of receiving study drug. If FAB classification is
             Refractory anemia (RA) or Refractory anemia with ringed sideroblasts (RARS), then must
             be red cell transfusion dependent, defined as needing red cells more frequently than
             once every 4 weeks.

          4. If receiving erythropoietin(Procrit), must have been on a stable dose for at least 8
             weeks before first dose of study drug.

          5. If receiving darbepoetin(Aranesp), must have been on a stable dose for at least 12
             weeks before first dose of study drug.

        Exclusion Criteria:

          1. Must not have a diagnosis of Acute Myeloid Leukemia (AML) or other progressive
             malignant disease.

          2. Must not have received any investigational agent within the 30 days preceding the
             first dose of study drug.

          3. Must not have uncontrolled cardiac disease or uncontrolled congestive heart failure.

          4. Must not have an active viral or bacterial infection.
Clinical trial NCT00655538 (phase 2, status: completed)
Conditions: coronary heart disease
ICD codes: I25.10, I25.110, I25.119, I25.111, I25.118
Drugs: placebo, dalcetrapib
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CCC(CC)CC1(CCCCC1)C(=O)NC1=CC=CC=C1SC(=O)C(C)C
Eligibility criteria:

        Inclusion Criteria:

          -  adult patients, 18-75 years of age;

          -  CHD or CHD risk equivalent;

          -  appropriately treated for accepted LDL-C level.

        Exclusion Criteria:

          -  treatment with drugs raising HDL-C (eg niacin, fibrates);

          -  uncontrolled hypertension;

          -  recent (within 3 months) clinically significant coronary events, transient ischemic
             attacks or cerebrovascular accident;

          -  severe anemia;

          -  poorly controlled diabetes.
Clinical trial NCT01064037 (phase 2, status: terminated)
Conditions: heart failure, heart decompensation
ICD codes: I50.814, I09.81, I50.82, I50.89, I50.9, T86.22, I11.0
Drugs: cinaciguat (bay58-2667), cinaciguat (bay58-2667), cinaciguat (bay58-2667), placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Male and non-pregnant, non-lactating female subjects, age >/= 18 years of age; or
             women without childbearing potential defined as postmenopausal women aged 55 years or
             older, women with bilateral tubal ligation, women with bilateral ovarectomy, and women
             with a hysterectomy

          -  Subjects must have the clinical diagnosis of congestive heart failure (CHF) made at
             least three months prior to enrollment

          -  Subjects must experience worsening of both of the symptoms below leading to
             hospitalization at the time of entry into the study: dyspnea and clinical evidence of
             volume overload

        Exclusion Criteria:

          -  Acute de-novo heart failure

          -  Acute myocardial infarction and/or myocardial infarction within 30 days

          -  Valvular heart disease requiring surgical intervention during the course of the study

          -  Heart failure due to or associated with uncorrected primary valvular disease,
             malfunctioning artificial heart valve, or uncorrected congenital heart disease

          -  Primary hypertrophic cardiomyopathy

          -  Acute inflammatory heart disease, eg, acute myocarditis

          -  Unstable angina requiring angiography
Clinical trial NCT00518206 (phase 2, status: completed)
Conditions: melanoma
ICD codes: C43.0, C43.31, D03.9, C43.51, C43.9, D03.0, C43.4
Drugs: cyclophosphamide
SMILES: ClCCN(CCCl)P1(=O)NCCCO1
Eligibility criteria:

        Inclusion Criteria:

          1. Stage IV (metastatic) or unresectable stage III malignant melanoma.

          2. Measurable disease using RECIST.

          3. No other effective therapy available or appropriate.

          4. Expression of NY-ESO-1 or LAGE-1 by immunohistochemistry (IHC) or reverse
             transcription-polymerase chain reaction (RT-PCR).

          5. Expected survival of at least 4 months.

          6. Karnofsky performance status of ≥ 70%.

          7. Within 3 weeks prior to first administration of study drug, the following laboratory
             parameters were required to be within the ranges specified:

               -  Hemoglobin ≥ 100 g/L

               -  Platelets ≥ 100 x 10^9/L

               -  International normalized ratio ≤ 2.0

               -  Creatinine ≤ 0.2 mmol/L

               -  Bilirubin ≤ 30 mmol/L

          8. Age ≥ 18 years.

          9. Able and willing to give written informed consent.

        Exclusion Criteria:

          1. Other serious illnesses, eg, serious infections requiring antibiotics, bleeding
             disorders, or any condition that in the opinion of the Investigator would have
             interfered with the ability of the patient to complete all study requirements.

          2. Other malignancy within last 3 years, except for treated melanoma or non-melanoma skin
             cancer or cervical cancer in situ.

          3. Known immunodeficiency.

          4. Known human immunodeficiency virus positivity.

          5. Concomitant systemic treatment with corticosteroids, anti-histaminic drugs, or
             nonsteroidal anti-inflammatory drugs. Specific cyclooxygenase-2 (COX-2) inhibitors,
             low-dose aspirin for the prevention of an acute cardiovascular event, and topical or
             inhaled steroids were permitted.

          6. Chemotherapy and/or radiotherapy within 4 weeks prior to study week 1.

          7. Other immunotherapy within 4 weeks prior to study week 1.

          8. Mental impairment that may have compromised the ability to give informed consent and
             comply with the requirements of the study.

          9. Lack of availability for immunological and clinical follow-up assessment.

         10. Participation in any other clinical trial involving another investigational agent
             within 4 weeks prior to enrollment.

         11. Pregnancy or breastfeeding.

         12. Women of childbearing potential: refusal or inability to use effective means of
             contraception.
Clinical trial NCT00585689 (phase 2, status: completed)
Conditions: bladder cancer
ICD codes: D30.3, C67.5, C67.9, C79.11, C67.0, C67.1, D41.4
Drugs: abi-007, carboplatin, gemcitabine
SMILES: [H][C@]12[C@H](OC(=O)C3=CC=CC=C3)[C@]3(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)C4=CC=CC=C4)C4=CC=CC=C4)C(C)=C([C@@H](OC(C)=O)C(=O)[C@]1(C)[C@@H](O)C[C@H]1OC[C@@]21OC(C)=O)C3(C)C, N[C@@H](CCCNC(N)=N)C(O)=O, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1
Eligibility criteria:

        Inclusion Criteria:

          -  Histologically proven locally advanced (T2-4,N0,M0 or Tany,N1-3,M0) urothelial
             carcinoma of the bladder and be candidates for cystectomy following chemotherapy.
             Tumor specimens must be available for assay of molecular markers (correlative
             research).

          -  Performance status of 0, 1 or 2 by Eastern Cooperative Oncology Group (ECOG) criteria.

          -  Serum creatinine <2.0 mg/dl and/or creatinine clearance >40 ml/min.

          -  Granulocyte count > 1,500/mm3, platelet > 100,000/mm3, and hemoglobin > 9.0 g/dl.

          -  Adequate liver functions: AST and ALT < 2.5 X upper limit of normal, alkaline
             phosphatase < 2.5 X upper limit of normal, and bilirubin < 1.5 mg/dl.

          -  Pre-existing peripheral neuropathy > grade 2

          -  Recovered from any effects of surgery.

          -  Women/men of reproductive potential may not participate unless they have agreed to use
             an effective contraceptive method. Women with reproductive potential must have a
             negative pregnancy test.

        Exclusion Criteria:

          -  Prior systemic or intra-arterial chemotherapy and rior radiotherapy. (intravesical
             chemotherapy allowed.)

          -  Pre-existing peripheral neuropathy > grade 2

          -  Prior malignancy [except for adequately treated basal cell (or squamous cell) skin
             cancer, in situ cervical cancer or other cancer for which the patient has been disease
             free for 2 years]

          -  Unresolved bacterial infection requiring active treatment with antibiotics. (Treatment
             may begin at the conclusion of antibiotic therapy.)

          -  Pregnant or lactating women may not participate.
Clinical trial NCT00269152 (phase 2, status: completed)
Conditions: non-small cell lung cancer
ICD codes: C78.00, C78.01, C78.02, D14.30, D14.31, D14.32, C34.2
Drugs: pemetrexed, cisplatin, carboplatin
SMILES: [H][N]([H])([H])[Pt](Cl)(Cl)[N]([H])([H])[H], [H][C@@]12N(C)C3=CC(OC)=C(C=C3[C@@]11CCN3CC=C[C@](CC)([C@@]13[H])[C@@]([H])(OC(C)=O)[C@]2(O)C(=O)OC)[C@]1(C[C@@]2([H])CN(CC(CC)=C2)CC2=C1NC1=CC=CC=C21)C(=O)OC, N[C@@H](CCCNC(N)=N)C(O)=O
Eligibility criteria:

        Inclusion Criteria:

          -  Histologically proven non-small cell lung cancer stage Ib, IIa or IIb

          -  Must have complete tumor resection by pneumonectomy or lobectomy

          -  Must have been surgically proven to be N2 negative

        Exclusion Criteria:

          -  Serious concomitant systemic disorder

          -  Post-operative complications or other surgery related conditions

          -  A prior malignancy other than NSCLC unless that malignancy was diagnosed and treated
             at least 5 years ago
Clinical trial NCT00352417 (phase 2, status: completed)
Conditions: atherosclerosis
ICD codes: I67.2, I70.90, I70.91, I70.0, I70.1, I70.8, I25.83
Drugs: via-2291, placebo
SMILES: C[C@H](C#CC1=CC=C(CC2=CC=C(F)C=C2)S1)N(O)C(N)=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Female patients must be of non-childbearing potential

          -  Carotid stenosis between 60% and 90% and to be scheduled for CEA surgery

          -  One or more of the following clinical features: Prior history >4 weeks of
             cerebrovascular accident (CVA) or transient ischemic attack (TIA) consistent with
             North American Symptomatic Carotid Endarterectomy Trial (NASCET) criteria or prior
             history of amaurosis fugax occurring at any time

          -  Diabetes haemoglobin (Hb) A1c between 7.0 and 11% or a history of two or more fasting
             blood glucose levels >6.9 mmol/L

          -  Baseline hsCRP >2 mg/L

          -  Echolucent plaque

        Exclusion Criteria:

          -  Acute CVA or TIA within 4 weeks of enrollment or the presence of ulcerated or unstable
             plaque requiring urgent carotid endarterectomy

          -  Renal insufficiency defined as creatinine >1.5 x upper limit of normal (ULN)

          -  Cirrhosis, recent hepatitis, alanine aminotransferase (ALT) >1 x ULN (i.e., above the
             normal range) or positive screening test for hepatitis B (hepatitis B surface antigen)
             or hepatitis C (by ELISA)

          -  Uncontrolled diabetes mellitus within 1 month prior to study screening, defined as
             HbA1c >11% at screening

          -  Congestive heart failure (CHF) defined by the New York Heart Association as functional
             Class III or IV

          -  Recent acute coronary syndrome event or coronary artery bypass graft (CABG) surgery
             (within 4 weeks of enrollment)

          -  Current atrial fibrillation

          -  Planned cardiac intervention

          -  Acetaminophen use in any form in the 7 days before enrollment
Clinical trial NCT00237536 (phase 2, status: terminated)
Conditions: benign prostatic hyperplasia
ICD codes: N40.0, N40.1
Drugs: lonidamine
SMILES: OC(=O)C1=NN(CC2=C(Cl)C=C(Cl)C=C2)C2=C1C=CC=C2
Eligibility criteria:

        Inclusion Criteria:

          1. Capable of understanding the purpose and risks of the study and sign a statement of
             informed consent

          2. Male 65-80 years of age (or 40-80 with vasectomy). Vasectomized men must have
             documentation of azoospermia.

          3. Presence of LUTS (lower urinary tract symptoms) for at least 3 months

          4. Prostate volume measured by TRUS (transrectal ultrasound) > 30 cc

          5. Qmax < 15 mL/sec when measured by uroflowmetry (minimum of 125 mL must be voided)

          6. IPSS (International Prostate Symptom Score) > 12

          7. PSA > 1.0 ng/mL

          8. Must ensure and consent to use medically acceptable methods of contraception
             throughout the entire study with sexual partners of childbearing potential

          9. Able to comply with the prescribed treatment protocol and evaluations

        Exclusion Criteria:

          1. Prior treatment for BPH with alpha blockers and/or herbal supplements for the
             treatment of BPH in the past 2 weeks (alpha-blockers and/or herbal supplements for the
             treatment of BPH are not allowed during the study). Prior treatment with 5-alpha
             reductase inhibitors is allowed if discontinued at least 3 months prior to enrollment.

          2. Prior surgery of the prostate (except biopsies; subject is eligible to enroll one
             month after full recovery from prostate biopsy.)

          3. Current or past evidence of malignant disease of the prostate or prostatic
             intraepithelial neoplasia (For subjects with PSA between 4 - 10 ng/mL, prostate cancer
             must be ruled out to the satisfaction of the Principal Investigator. Subjects with PSA
             >10 ng/mL are excluded).

          4. Active urinary tract infections (UTI)

          5. Active cardiac, renal or hepatic disease as evidenced by:

               1. Serum creatinine > 1.8 mg/dL

               2. ALT or AST > 2.5x the upper limit of normal

               3. History of active myocardial infarction, unstable cardiac arrhythmias, or stroke
                  within 6 months prior to screening

               4. Uncontrolled congestive heart failure

          6. Uncontrolled diabetes mellitus (fasting blood glucose > 200 mg/dL)

          7. Use of systemic steroids for any reason (systemic steroid usage is not allowed during
             the study). Inhaled and/or topical steroids are allowed.

          8. Concurrent participation or participation in an investigational drug study within the
             past 30 days prior to screening

          9. Concomitant disease or condition that could interfere with the conduct of the study,
             or would in the opinion of the Investigator, pose an unacceptable risk to the subject
Clinical trial NCT00100048 (phase 2, status: completed)
Conditions: hiv infections, acquired immunodeficiency syndrome
ICD codes: Z21, D84.9, D81.9, D83.9, D84.821, B20, D82.2, D84.822
Drugs: comparator: mk0518 monotherapy, comparator: mk0518 combination therapy, comparator: efavirenz, comparator: tenofovir, comparator: lamivudine, placebo monotherapy
SMILES: FC(F)(F)[C@]1(OC(=O)NC2=C1C=C(Cl)C=C2)C#CC1CC1, [H][C@@](C)(CN1C=NC2=C(N)N=CN=C12)OCP(=O)(OCOC(=O)OC(C)C)OCOC(=O)OC(C)C, NC1=NC(=O)N(C=C1)[C@@H]1CS[C@H](CO)O1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Patient must be HIV positive who must have received less than 7 days total of any
             antiretroviral therapy (HIV related therapy)

        Extension Studies:

          -  First extension: Patient completed the 48-week base study

          -  Second extension: Patient completed the first 144-week extension study

        Exclusion Criteria:

          -  Less than 18 years of age

          -  Individuals who currently do not test positive for HIV
Clinical trial NCT00606450 (phase 2, status: completed)
Conditions: psoriasis
ICD codes: L40.0, L40.4, L40.8, L40.9, L40.1, L40.50
Drugs: cc-10004, cc-10004, placebo
SMILES: [H][C@](CS(C)(=O)=O)(N1C(=O)C2=C(C1=O)C(=CC=C2)N=C(C)O)C1=CC(OCC)=C(OC)C=C1, [H][C@](CS(C)(=O)=O)(N1C(=O)C2=C(C1=O)C(=CC=C2)N=C(C)O)C1=CC(OCC)=C(OC)C=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Must understand and voluntarily sign and informed consent form

          -  Must be in good health as judged by the investigator

          -  Must be able to adhere to the study visit schedule and other protocol requirements

          -  Must have greater than or equal to a 6 month history of moderate-to-severe plaque-type
             psoriasis

          -  Must have a Psoriasis Area and Severity Index (PASI) score greater than or equal to 10
             and Body Surface Area (BSA) greater than or equal to 10%

          -  Must meet specific laboratory criteria

          -  Must be a candidate for photo/systemic therapy

          -  Women of childbearing potential must have a negative pregnancy test

        Exclusion Criteria:

          -  Must not have clinically significant underlying disease processes

          -  Must not be pregnant or lactating females

          -  Must not have any condition, including lab abnormalities, which places the subject at
             unacceptable risk if the subject were to participate in the study or confounds the
             ability to interpret data from the study

          -  Must not have a history of active mycobacterium tuberculosis infection within 3 years
             prior to the screening visit

          -  Must not have a history of incompletely treated active of latent mycobacterium
             tuberculosis infection

          -  Must not have a know history of exposure to an infectious case of mycobacterium
             tuberculosis within 2 years prior to the screening visit

          -  Must not be an immigrant form a high-incidence country for mycobacterium tuberculosis
             disease within 2 years prior to the screening visit

          -  Must not have current erythrodermic, guttate, or pustular psoriasis

          -  Must not have a clinical history of failure to adequately respond to treatment in the
             investigator's opinion to one or more treatment courses of cyclosporine or the
             following biologic therapies: alefacept, etanercept, efalizumab, infliximab or
             adalimumab

          -  Must not use topical therapy within 14 days of randomization

          -  Must not use systemic therapy for psoriasis within 28 days of randomization

          -  Must not use phototherapy within 28 days of randomization

          -  Must not use adalimumab or infliximab within 3 months of randomization

          -  Must not use etanercept or efalizumab within 56 days of randomization

          -  Must not use alefacept within 6 months of randomization
Clinical trial NCT01601613 (phase 2, status: completed)
Conditions: acquired bleeding disorder, dengue haemorrhagic fever
ICD codes: D68.311, L85.0, H53.62, I77.0, L11.0, L68.1, N48.83
Drugs: activated recombinant human factor vii, placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Patients with the clinical diagnosis of Dengue Haemorrhagic Fever (DHF)

          -  Patients with a clinical diagnosis of DHF Grades II and III8, requiring standard
             replacement therapy

        Exclusion Criteria:

          -  Patients with a clinical diagnosis of DHF Grade IV

          -  Known or suspected allergy to trial product or related products

          -  Known hypersensitivity to mouse, hamster or bovine protein

          -  Prior treatment with activated recombinant human factor VII